{"id":475,"date":"2026-04-12T09:40:23","date_gmt":"2026-04-12T09:40:23","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=475"},"modified":"2026-08-30T03:53:24","modified_gmt":"2026-08-30T03:53:24","slug":"luciale-alectinib-75-mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/ar\/product\/luciale-alectinib-75-mgx30-tablets\/","title":{"rendered":"LuciAle"},"content":{"rendered":"<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>HIGHLIGHTS OF PRESCRIBING INFORMATION&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>These highlights do not include all the information needed to use LuciAle safely and effectively. See full prescribing information for LuciAle.<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>INDICATIONS AND USAGE<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">LuciAle is a kinase inhibitor indicated for:<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors \u2265 4 cm or node positive) as detected by an FDAapproved test.&nbsp;<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>DOSAGE AND ADMINISTRATION&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">600 mg orally twice daily. Administer LuciAle with food.&nbsp;<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>DOSAGE FORMS AND STRENGTHS&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">Tablets: 75 mg\u00d730 tablets<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>CONTRAINDICATIONS&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">None.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>WARNINGS AND PRECAUTIONS&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Hepatotoxicity: Monitor liver laboratory tests every 2 weeks during the first 3 months of treatment, then once a month and as clinically indicated, with more frequent testing in patients who develop transaminase and bilirubin elevations. In case of severe ALT, AST, or bilirubin elevations, withhold, then reduce dose, or permanently discontinue LuciAle.&nbsp;<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Interstitial Lung Disease (ILD)\/Pneumonitis: Immediately withhold LuciAle in patients diagnosed with ILD\/pneumonitis and permanently discontinue if no other potential causes of ILD\/pneumonitis have been identified.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Renal Impairment: Withhold LuciAle for severe renal impairment, then resume LuciAle at reduced dose upon recovery or permanently discontinue.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, withhold LuciAle then reduce dose, or permanently discontinue.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Severe Myalgia and Creatine Phosphokinase (CPK) Elevation: Assess CPK every 2 weeks during the first month of treatment and in patients reporting unexplained muscle pain, tenderness, or weakness. In case of severe CPK elevations, withhold, then resume or reduce dose.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Hemolytic Anemia: If hemolytic anemia is suspected, withhold LuciAle. If hemolytic anemia is confirmed, consider resuming at a reduced dose upon resolution or permanently discontinue.&nbsp;<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">\u2022 Embryo-Fetal Toxicity: LuciAle can cause fetal harm. Advise femalesof reproductive potential of the potential risk to a fetus and to use effective contraception.&nbsp;<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>ADVERSE REACTIONS&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">The most common adverse reactions (incidence \u226520%) were hepatotoxicity, constipation, fatigue, myalgia, edema, rash and cough.&nbsp;<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>USE IN SPECIFIC POPULATIONS&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">Lactation: Do not breastfeed.<\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><br \/><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\"><strong>Storage&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"white-space: nowrap;font-size:16px;color:#595959\">Store at 20C to 25C (68F to 77F), excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;<\/span><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciAle is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.<\/p>","protected":false},"featured_media":1855,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[19],"product_tag":[],"class_list":["post-475","product","type-product","status-publish","has-post-thumbnail","product_cat-lung-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product\/475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/comments?post=475"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media\/1855"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media?parent=475"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_brand?post=475"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_cat?post=475"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_tag?post=475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}